NuVasive, Inc. provided sales guidance for the full year 2023. For the period, the company expects net sales growth of 6%?8% on an as reported and constant currency basis, compared to full year 2022, based on foreign currency rates as of July 31, 2023.
NuVasive, Inc.
Equities
NUVA
US6707041058
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |